Home›Screener›SANA›Profile
D
41/100

Sana Biotechnology

SANACell Engineering
← Signals View
📋
Analyst Summary
✓ VERIFIED2026-04-11

Sana Biotechnology (SANA) is the lead sponsor of 3 active clinical trials listed on ClinicalTrials.gov[2], including 3 Phase 1[1].

SANA has 1 Form 4 insider filing recorded at the SEC in the past 30 days[3].

Sources

  1. ClinicalTrials.gov (2026-04-11) ↗
  2. ClinicalTrials.gov (2026-04-11) ↗
  3. SEC EDGAR · 0001770121 (2026-04-11) ↗
🔬
Clinical Trials
3
NCT05878184Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
NCT06285422Non Hodgkin's Lymphoma, Large B-cell Lymphoma
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
NCT06294236Lupus Erythematosus, Systemic Lupus Erythematosus, SLE (Systemic Lupus), Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Granulomatous Polyangiitis, Microscopic Polyangiitis
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
👤
Insider Activity
1
1 filing
Source ↗
sec_edgar · Retrieved 2026-04-11
Not financial advice. BiotechSigns profiles are AI-generated from verified public sources (ClinicalTrials.gov, SEC EDGAR) and are for informational purposes only. Always do your own due diligence before making investment decisions.
Score Breakdown
Score Trend
2026-04-132026-06-02
Signal Summary
PDUFA Dates0
Insider Filings1
Clinical Trials2
Data Provenance
cik1 verified
clinical trial3 verified
insider buy1 verified
trial count2 verified
Every claim backed by source URL from ClinicalTrials.gov or SEC EDGAR